Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

The pharmaceutical giant introduces higher-dose vials and reduces costs to increase affordability for uninsured patients and counter competition.

Eli Lilly has launched 7.5 mg and 10 mg vials of its weight-loss drug Zepbound, priced at $499 per month for patients paying without insurance through LillyDirect.
The prices for lower-dose vials (2.5 mg and 5 mg) have been reduced to $349 and $499 per month, respectively, further expanding affordability options.
The vials are part of Lilly's direct-to-consumer program, which bypasses third-party supply chains to provide lower prices for self-paying patients.
This move comes as Eli Lilly aims to compete with Novo Nordisk's Wegovy and address the market previously served by compounded versions of weight-loss drugs, which are being phased out after FDA shortages ended.
Lilly's efforts also highlight the broader issue of limited insurance coverage for obesity treatments, sparking calls for systemic changes to improve accessibility.